Immunological studies on sporamycin-treated animals.

Publisher Website
Google Scholar
Abstract
Sporamycin showed a remarkable tumor regressive activity against [mouse] sarcoma 180 cells with a single 5 mg/kg dose of i.v. administration. This antitumor effect on tumor and host animals was examined immunologically. When sarcoma 180 tumor cells were used as an antigen, macrophage migration inhibition reaction by spleen cells derived from the tumor-bearing mice treated with sporamycin was positive at day 7-14 after the medication and was negative thereafter. The delayed hypersensitivity tested by the foot-pad reaction was positive in tumor-bearing mice treated with sporamycin and no decrease of foot pad reaction was observed; this reaction decreased remarkably in non-treated tumor-bearing mice. Sarcoma-180 tumor cells were mixed with spleen cells derived from sporamycin-treated mice and were inoculated into normal dd mice. The growth of tumor cells was inhibited markedly; no inhibition of tumor growth was observed in the case of spleen cells derived from non-treated tumor bearing mice. Combined treatment of sporamycin with PS-K [protein bound polysaccharide Kuerka], an immunopotentiator, showed a remarkable synergistic effect.